Coherent Inc.
This article was originally published in The Gray Sheet
Executive Summary
Submits 510(k) submission to FDA for the Selecta 7000 selective laser trabeculotherapy (SLT) laser system for treatment of open angle glaucoma. SLT lowers intraocular pressure using a laser to increase the fluid outflow of the eye, the firm explains. The procedure provides an alternative to current pharmacological solutions and laser techniques. Coherent estimates that as many as 300,000 U.S. patients are currently eligible for SLT